Application of atractylodes macrocephala koidz polysaccharide in preparation of medicine for treating diabetes-related diseases
Atractylodes macrocephala polysaccharide prepared by water ingestion method solves the treatment problems of diabetic nephropathy and diabetic intestinal diseases, improves renal function and intestinal barrier function, significantly reduces the inflammation and fibrosis of diabetic nephropathy, and provides new Treatment strategies.
Patent Information
- Application Number
- CN202411200144.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The prior art lacks effective drugs in the treatment of diabetic nephropathy and diabetic intestinal diseases. Traditional methods such as renin-angiotensin system inhibitors are not sufficient to prevent the progress of diabetic nephropathy, and the absorption and metabolism of biologically active ingredients of traditional Chinese medicine in the intestines. Inefficient, affecting the treatment effect.
Atractylodes polysaccharide prepared by water alcohol extraction and precipitation method, high-purity atractylodes polysaccharide is obtained through multiple hot water extraction and ethanol precipitation methods. It is used to treat diabetic nephropathy and diabetic intestinal diseases, and regulate intestinal flora and intestinal mucosal barrier function. , repairs the expression of the signature protein in the intestinal epithelium.
Atractylodes macrocephala polysaccharide can improve renal function damage and inflammation in diabetic nephropathy, repair intestinal mucosal barrier, regulate the expression of tight junction proteins, significantly reduce the expression of macrophage marker CD68 in the kidneys, and improve intestinal flora disorders in diabetic intestinal diseases. , delay the progress of diabetic nephropathy.
Smart Images

Figure CN119015304A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines and relates to a kind of Atractylodes macrocephala polysaccharide, and particularly relates to the application of the Atractylodes macrocephala polysaccharide in preparing medicines for treating diabetes-related diseases. Background Art
[0002] Diabetic kidney disease (DKD) is a chronic kidney disease (CKD) caused by diabetes mellitus (DM). It is one of the major microvascular complications of diabetes and the most common cause of end-stage renal disease (ESRD) worldwide. Diabetic nephropathy gradually develops when hyperglycemia occurs, from low-grade renal inflammation to renal fibrosis, renal sclerosis, and finally ESRD. Epidemiological studies have shown that diabetes is one of the fastest growing global health emergencies in the 21st century. With the prevalence of diabetes, the incidence of DKD has shown a rapid growth trend. About 30%-40% of diabetic patients develop DKD, and one-third of patients further develop ESRD. DKD poses a huge challenge to my country's medical and health system and has caused a huge social and economic burden, but there is currently a lack of effective drugs to delay or reverse the progression of DKD.
[0003] Pathologically, multiple changes occur in the kidneys of patients with DKD. Capillary lumen dilation, basement membrane thickening, extracellular matrix expansion, podocyte damage, and fibrosis are common in the glomeruli; while in the tubulointerstitium, vacuolar degeneration, loose arrangement, and fibrosis can be observed. Patients are usually identified as glomerular hyperfiltration, microalbuminuria, and macroalbuminuria, and then as DKD progresses, the glomerular filtration rate (GFR) decreases. In clinical practice, urine protein (UP) levels, including urine albumin excretion rate (UAER) in patients with microalbuminuria or 24-hour UP in patients with macroalbuminuria, are usually regarded as the main indicators for detecting DKD. So far, the treatment and management strategies of DKD are mainly to reduce weight, blood sugar, and blood pressure, and renin-angiotensin system inhibitors (RASIs) including angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are commonly used first-line treatments. However, satisfactory results are not always achieved when these traditional methods are used to treat DKD. For example, it has been reported that ARBs are insufficient to prevent the progression of albuminuria in normotensive DM patients. Traditional Chinese medicine (TCM) has a long history as a commonly used drug for the treatment of DM and related complications such as DKD, and has good effects in clinical practice. Some bioactive compounds in TCM that are beneficial to patients with diabetic nephropathy have been identified and purified, and their mechanisms of action have been extensively studied. Studies have shown that TCM treatment can improve renal function and alleviate symptoms such as proteinuria and glomerulosclerosis. Therefore, exploring TCM with potential hypoglycemic effects may provide a possibility for the prevention and treatment of DM and related complications.
[0004] Traditional Chinese medicine polysaccharides are a class of natural high molecular compounds widely found in Chinese herbal medicines, with important pharmacological activities and rich biologically active components. In the past few decades, with the continuous development of biotechnology and modern chemical technology, the research on traditional Chinese medicine polysaccharides has received more and more attention. Traditional Chinese medicine polysaccharides have a variety of biological activities, such as immunomodulation, antioxidant, anti-tumor, antiviral, liver protection, lipid-lowering and other effects. At present, Chinese medicine polysaccharides have been widely studied in the field of glucose and lipid metabolic diseases. Lycium barbarum polysaccharides and astragalus polysaccharides have been shown to lower blood sugar. The mechanism of action of these polysaccharides may be related to promoting insulin secretion, promoting glucose transport, inhibiting glycogenase, etc.; donkey-hide gelatin polysaccharides and ganoderma lucidum polysaccharides have been shown to play a role in lowering blood lipids by inhibiting fat synthesis, promoting fat decomposition, and regulating cholesterol metabolism; diabetic patients are often accompanied by oxidative stress, and Poria cocos polysaccharides and cinnamon twig polysaccharides have significant antioxidant effects, and their mechanism of action may be related to inhibiting the production of free radicals and increasing the activity of antioxidant enzymes; in terms of immune regulation, ganoderma lucidum polysaccharides and Lycium barbarum polysaccharides have been shown to play a role in regulating immunity by enhancing the body's immunity and regulating the function of immune cells. In short, as a class of natural drug resources, Chinese medicine polysaccharides have a wide range of pharmacological activities and application prospects. With the continuous deepening of research, it is believed that more biological activities and pharmacological effects of Chinese medicine polysaccharides will be discovered and applied, providing possibilities for the prevention and treatment of DM-related complications.
[0005] There are a large number of microorganisms living in the gastrointestinal tract of healthy people. These microorganisms are called intestinal microbiota, and they constitute a huge and complex ecosystem. Studies have shown that the intestinal microbiota is an important part of the intestinal microecological system and plays a key role in the host physiological functions and processes of the human body, such as nutrient absorption, growth and development, biological barriers, immune regulation, fat metabolism and anti-tumor activity. Under normal circumstances, the human intestinal flora forms a dynamic equilibrium system, restrains each other, and jointly maintains the microecological balance in the human body, participates in the human body's digestion, metabolism, immune regulation, energy conversion, and maintains intestinal mucosal defense and other functions. Once affected by changes in the host itself and the external environment, the balance between the host and the flora will be broken, causing an imbalance in the intestinal microecological system, which will lead to impaired body function and disease.
[0006] Diabetic patients often suffer from intestinal diseases, including intestinal mucosal damage, imbalance of intestinal microbiome homeostasis, barrier damage, decreased immune function, etc. Severe cases may induce complications such as stroke, coronary artery obstruction, retinopathy, and dysfunction and failure of tissues and organs such as the liver and kidneys.
[0007] In recent years, the interaction between the bioactive components of traditional Chinese medicine (TCM) and the intestinal microbiota has become the focus of many studies. When TCM enters the digestive tract, some bioactive components are not well absorbed by the intestine, resulting in low bioavailability. TCM components are metabolized or biotransformed by the intestinal microbiota, thereby producing new bioactive molecules and promoting drug absorption into the circulation. At the same time, TCM components affect the composition and structure of the intestinal microbiota, thereby affecting the remote functions of diseased organs / tissues through the systemic effects of the intestinal microbiota. Studies have shown that TCM polysaccharides can increase the number of beneficial intestinal flora such as bifidobacteria and lactic acid bacteria, and inhibit the growth of harmful flora such as Escherichia coli and enterococci. These beneficial flora can produce beneficial metabolites such as short-chain fatty acids, which help maintain the integrity of the intestinal mucosal barrier, inhibit inflammatory responses, and promote nutrient absorption and metabolism. In addition, some Chinese herbal polysaccharides themselves have the function of regulating intestinal metabolism. For example, astragalus polysaccharides can lower blood sugar, blood lipids and body weight by regulating intestinal flora and metabolism; aloe polysaccharides can improve intestinal barrier function and prevent diseases such as enteritis by promoting the growth and metabolism of beneficial bacteria.
[0008] The intestinal flora is a microbial community closely associated with the host. It plays an important role in maintaining intestinal balance and is involved in the occurrence and development of metabolic diseases such as obesity, diabetes and CKD. Intestinal flora dysbiosis includes structural changes and functional abnormalities. Changes in the structure of the intestinal flora are often manifested as a significant decrease in probiotics and the proliferation of opportunistic pathogens, accompanied by changes in the function of the intestinal flora, which affects physiological processes such as host material and energy metabolism and immune response, increases the risk of disease, and forms a vicious cycle. The destruction of the intestinal barrier is an important cause of metabolic inflammation in the body. Unhealthy eating habits, such as high-sugar and high-fat diets, can cause changes in the composition of the intestinal microbiota, promote the growth of pathogens, and inhibit the growth of symbiotic bacteria. With the increase of invasive pathogens, these bacteria can degrade intestinal mucus and reach the epithelial barrier. Subsequently, the bacterial component LPS binds to TLRs on the surface of intestinal epithelial cells, recruits immune cells in the intestine, releases proinflammatory factors such as IFN-γ and IL-1β, inhibits the expression of intestinal tight junction proteins, destroys the intestinal epithelial barrier, promotes the passage of intestinal bacteria through the intestinal plate, and further destroys the intestinal vascular barrier. Recent studies have shown that the intestinal microbiota is involved in the progression of DKD. Bacterial metabolites have been shown to influence the development and progression of chronic kidney disease, and progression to renal failure leads to worsening of intestinal microbiota dysbiosis.
[0009] CKD patients often suffer from intestinal bacterial dysbiosis, accumulation of bacterial metabolites, disruption of intestinal barrier function, and chronic inflammation. Most CKD patients have intestinal bacterial overgrowth, but bacterial diversity is reduced. In addition, Eggerthellalenta, Flavonifractor spp., Alistipes spp., Ruminococcus spp., and Fusobacterium spp. are significantly enriched in ESRD patients, while the abundance of bacteria producing short-chain fatty acids (SCFAs), especially butyrate, gradually decreases with the malignant development of ESRD. It has been reported that remodeling the intestinal microbiota can partially improve diabetes-related kidney damage by inhibiting oxidative stress and inflammation. The enrichment of bacteria producing SCFAs (i.e., acetate, butyrate, and propionate) inhibits the development of the disease by regulating intestinal inflammation and host immunity. Therefore, the intestinal flora and derived metabolites may serve as new therapeutic targets for DKD.
[0010] Previous studies have shown that Chinese medicine and its natural extracts may have specific protective effects on renal function. These effects can slow the progression of kidney disease, but the exact mechanisms remain incompletely understood. It is speculated that plant polysaccharides may exert their pharmacological effects by regulating the intestinal microbiota, restoring the integrity of the intestinal barrier, and inhibiting inflammation. Therapeutic strategies targeting the intestinal flora have great potential in the future and will open up an emerging perspective and direction for the treatment of DKD.
[0011] Traditional Chinese medicine polysaccharides, as a kind of biomacromolecule, are usually composed of 10 or more types of monosaccharides. In recent years, they have become the focus of research due to their diverse biological activities. This type of polysaccharide is a long-chain polymer carbohydrate formed by connecting multiple monosaccharide units through glycosidic bonds, which can produce monosaccharides or oligosaccharides when hydrolyzed. Its general formula is Cx(H2O)y, and the x value is usually between 200 and 2500. At present, there are various extraction methods for traditional Chinese medicine polysaccharides, which have a significant impact on the type, physicochemical properties and biological activity of the final extract. Hot water extraction and ethanol precipitation are the main extraction methods, which have the advantages of simple operation, no need for special equipment and low cost. Although some new extraction technologies have been developed to extract polysaccharides of different properties, due to technical limitations, the purity of the extracted polysaccharides is usually low. Therefore, the purification and structural identification of traditional Chinese medicine polysaccharides are particularly critical. The purification process is complicated, and it is difficult to obtain high-purity homogeneous polysaccharide components. More and more studies have shown that the extraction and purification methods have a significant impact on the modification and biological activity of polysaccharides. Therefore, the extraction and purification of traditional Chinese medicine polysaccharides is an important basis for analyzing their biological activity and chemical modification.
[0012] Studies have shown that polysaccharides are closely related to the regulation of immune function, cell division and differentiation, and the occurrence and development of diseases. Atractylodes macrocephala is a homologous plant that strengthens the spleen and replenishes qi, and polysaccharides are its active ingredients. Atractylodes macrocephala polysaccharides have strong activity in regulating intestinal microecological balance and intestinal mucosal immune function. In addition, Atractylodes macrocephala polysaccharides can reduce inflammatory damage and oxidative stress in mice, and play a protective role in the early stage of LPS invasion of the liver. Atractylodes macrocephala polysaccharides (AMPs) are important active ingredients in Atractylodes macrocephala and cannot be directly absorbed by the human body.
[0013] The invention patent with the publication number CN116726040A discloses the application of Atractylodes macrocephala polysaccharide in the preparation of drugs for the prevention and treatment of psoriasis. Atractylodes macrocephala polysaccharide is obtained by water extraction and alcohol precipitation, which specifically includes the following steps: after drying and crushing the Atractylodes macrocephala, adding water, extracting at 60-110°C for 0.5-8h, repeating the extraction several times, combining the extracts and filtering, concentrating, adding 70% or more ethanol solution to precipitate, standing at 4-30°C for 6-96h; filtering and collecting the precipitate to obtain a solution containing Atractylodes macrocephala polysaccharide, and freeze-drying to obtain Atractylodes macrocephala polysaccharide. Atractylodes macrocephala polysaccharide is composed of mannose, rhamnose, galacturonic acid, glucose, galactose and arabinose in a molar mass ratio of 2.48:6.17:3.58:66.82:9.10:11.68, and is mainly in β configuration.
[0014] The invention patent with publication number CN114073710A discloses a new use of Atractylodes macrocephala polysaccharide, namely, the use of Atractylodes macrocephala polysaccharide in the preparation of a health product or functional food that reduces the ratio of the relative abundance of Firmicutes (F) and Bacteroidetes (B) in the intestinal bacteria of spleen deficiency people, regulates the balance of intestinal bacteria F / B, and prevents or treats obesity caused by spleen deficiency and intestinal bacteria disorder. The Atractylodes macrocephala polysaccharide is a heteropolysaccharide composed of five monosaccharides, namely rhamnose (Rha), galacturonic acid (GalA), glucose (Glu), galactose (Gal) and arabinose (Ara), and has a specific fingerprint feature.
[0015] The invention patent with the publication number CN1398630A discloses a white atractylodes sugar complex with hypoglycemic activity, a production method and a use thereof, wherein the white atractylodes water extract is obtained by soaking, an organic solvent is precipitated, the precipitate is dissolved in water, the supernatant is subjected to dialysis or membrane separation and concentrated and dried to obtain a crude product, and the crude product is separated by column chromatography to obtain a refined white atractylodes sugar complex. The white atractylodes sugar element analysis: C = 35-45%, H = 5.5-7.0%, N = 1.0-3.0%; polysaccharide content: 40-60%; uronic acid content: 15-45%; protein content: 10-25%; monosaccharide composition: neutral sugars include glucose, galactose, mannose, arabinose and rhamnose, and also contain glucuronic acid and galacturonic acid. The polysaccharide has no toxic side effects and has obvious hypoglycemic function.
[0016] The extraction and purification methods have a significant impact on the modification and biological activity of polysaccharides. In order to seek effective, safe and low-toxic new therapeutic drugs for diabetic nephropathy, strategies need to be improved. Summary of the invention
[0017] In view of the problems existing in the prior art, the present invention provides an application of Atractylodes macrocephala in preparing a medicine for treating diabetes-related diseases. The Atractylodes macrocephala polysaccharide prepared by the water extraction and alcohol precipitation method can improve renal function damage, inflammation and renal fibrosis of diabetic nephropathy, repair the colon mucosal barrier function caused by diabetes, restore the expression of marker proteins of intestinal epithelium, regulate the expression of tight junction proteins Zo-1, E-cadherin, Ocln, Cldn2 and Cldn4, and can be used in medicines for regulating intestinal flora disorders caused by diabetic intestinal diseases.
[0018] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0019] In a first aspect, the present invention provides a use of Atractylodes macrocephala polysaccharide in the preparation of a medicament for treating diabetes-related diseases, wherein the diabetes-related diseases include diabetic nephropathy and / or diabetic intestinal disease.
[0020] Preferably, the Atractylodes macrocephala polysaccharide is used to prepare a drug for treating a mixed disease of diabetic nephropathy and diabetic intestinal disease, or diabetic nephropathy, wherein the diabetic nephropathy includes one or more of renal function damage, inflammation and renal fibrosis.
[0021] Preferably, the Atractylodes macrocephala polysaccharide is used to prepare a drug for treating a mixed disease of diabetic nephropathy and diabetic intestinal disease, or diabetic intestinal disease, wherein the diabetic intestinal disease is intestinal mucosal damage, and the intestinal mucosal damage is: the expression of tight junction proteins in the intestinal mucosa is inhibited or the intestinal flora is disturbed, and the tight junction proteins include one or more of Zo-1, E-cadherin, Ocln, Cldn2 and Cldn4.
[0022] The Atractylodes macrocephala polysaccharide is prepared by a water extraction and alcohol precipitation method, wherein the water extraction and alcohol precipitation method is as follows:
[0023] Extract Atractylodes macrocephala and ultrapure water in a ratio of 1 g: 15-25 mL, the extraction temperature is 85-95° C., preferably 90° C., the extraction times are 1-3 times, preferably 2 times, each extraction is 1-3 hours, the extracts are combined and concentrated to obtain a concentrated solution; 90-100% volume fraction of ethanol aqueous solution is added to the concentrated solution, the volume ratio of the concentrated solution to the ethanol aqueous solution is 1: 2-4, alcohol precipitation is performed to obtain a precipitate, and drying is performed to obtain Atractylodes macrocephala polysaccharide. Preferably, the obtained precipitate is washed with ethanol.
[0024] In one embodiment, the water extraction and alcohol precipitation method is specifically:
[0025] Step 1): extract Atractylodes macrocephala and ultrapure water at a ratio of 1 g: 20 mL at 90°C for 2 h, centrifuge at 4000×r for 20 min, and collect the supernatant and residue;
[0026] Step 2): extract and centrifuge the residue for the second time according to the method of step 1), combine the supernatants of the two extractions and concentrate at 60° C. to 1 / 3 of the original volume to obtain a concentrated solution;
[0027] Step 3): Add 3 times the volume of 95% ethanol aqueous solution to the concentrate, precipitate overnight at 4°C, centrifuge at 4000rpm for 10min, collect the precipitate, wash the precipitate twice with 95% ethanol aqueous solution, and freeze-dry to obtain Atractylodes macrocephala polysaccharide. The Atractylodes macrocephala polysaccharide is composed of 83.93% glucose, 7.19% arabinose, 5.47% galactose, 3.00% galacturonic acid and 0.41% glucuronic acid.
[0028] The surface of the Atractylodes macrocephala polysaccharide is loose and rough, and is in the shape of irregular multi-layer flakes or multi-layer rose petals.
[0029] The present invention provides a use of Atractylodes macrocephala polysaccharide in the preparation of a medicament for treating diabetes-related diseases, wherein the diabetes-related diseases include diabetic nephropathy and / or diabetic intestinal diseases. Compared with the prior art, the present invention has the following beneficial effects:
[0030] The present invention can protect renal function, renal structure and colon structure, alleviate inflammation and renal fibrosis caused by diabetic nephropathy, and reduce the expression of macrophage marker CD68 in the kidney by applying the prepared Atractylodes macrocephala polysaccharide to a drug for treating diabetic nephropathy.
[0031] The present invention uses the prepared Atractylodes macrocephala polysaccharide for the treatment of diabetic intestinal diseases, thereby repairing the colon mucosal barrier function caused by diabetic intestinal diseases, restoring the expression of marker proteins of the intestinal epithelium, regulating the expression of tight junction proteins Zo-1, E-cadherin, Ocln, Cldn2 and Cldn4, and improving diabetic intestinal diseases by regulating intestinal flora. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 This is the ion chromatogram of the monosaccharide composition of AMPs;
[0033] Figure 2 is the Fourier-infrared spectrum of AMPs;
[0034] Figure 3 is the scanning electron microscope image of AMPs;
[0035] Figure 4The mRNA levels of inflammatory factors Ccl2, Il-1β and Nlrp3 (# indicates significant difference compared with the CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates significant difference compared with the DKD group, *p<0.05, **p<0.01, ***p<0.001, ns indicates no significant difference compared with the DKD group);
[0036] Figure 5 Figure 2 is the mRNA level diagram of fibrosis-related indicators fibronectin (Fn1), collagen I (Col1a1) and transforming growth factor β1 (Tgfb1) (# indicates significant difference compared with CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates significant difference compared with DKD group, *p<0.05, **p<0.01, ***p<0.001, ns indicates no significant difference compared with DKD group);
[0037] Figure 6 Figure 2 is the mRNA level diagram of colon tight junction molecules Zo-1, E-cadherin, Ocln, Cldn2 and Cldn4 (# indicates significant difference compared with CON-FMT group, #p<0.05, ##p<0.01, ###p<0.001, * indicates significant difference compared with DKD-FMT group, *p<0.05, **p<0.01, ***p<0.001, ns indicates no significant difference compared with DKD group);
[0038] Figure 7 The figure is the effect of AMPs on the biochemical indexes of DKD mice, where A is the urine protein level of mice in each group, B is the ratio of urine protein / creatinine of mice in each group, and C is the serum creatinine content of mice in each group;
[0039] Figure 8 The effect of AMPs on the body weight and blood glucose of DKD mice. (A is the weight change of mice in 8 weeks; B is the fasting blood glucose of mice in the 8th week; # indicates a significant difference from the CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates a significant difference from the DKD group, *p<0.05, **p<0.01, ***p<0.001);
[0040] Fig. 9The effect of AMPs on glucose tolerance in DKD mice (A is the line graph of oral glucose tolerance test of mice in each group; B is the area under the curve (AUC) statistics of the OGTT line graph; # indicates a significant difference from the CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates a significant difference from the DKD group, *p<0.05, **p<0.01, ***p<0.001);
[0041] Fig.10 Mouse kidney morphology (A is the appearance of representative mouse kidneys in each group; B is the ratio of mouse kidney weight to body weight; C is kidney H&E staining; # indicates a significant difference from the CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates a significant difference from the DKD group, *p<0.05, **p<0.01, ***p<0.001);
[0042] Fig.11 The effect of AMPs on renal inflammation in DKD mice (A is CD68 immunohistochemical staining of mouse kidneys, scale bar = 20 μm; B is the statistics of CD68 positive area; # indicates significant difference compared with CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates significant difference compared with DKD group, *p<0.05, **p<0.01, ***p<0.001);
[0043] Fig.12 This is a diagram of the expression of MCP 1 and NLRP3 in the kidney of DKD mice detected by Western Blot; GAPDH was used as the internal standard for statistics (# indicates a significant difference compared with the CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates a significant difference compared with the DKD group, *p<0.05, **p<0.01, ***p<0.001);
[0044] Fig.13 The effect of AMPs on renal fibrosis in DKD mice (A is Masson staining of mouse kidney, scale bar = 20 μm; B is the statistics of the positive area of Masson staining; # indicates a significant difference from the CON group, #p < 0.05, ##p < 0.01, ###p < 0.001, * indicates a significant difference from the DKD group, *p < 0.05, **p < 0.01, ***p < 0.001);
[0045] Fig.14The effect of AMPs on tubulointerstitial fibrosis in DKD mice (A is CD68 immunohistochemical staining of mouse kidney, scale bar = 20 μm; B is the statistics of FN positive area; # indicates significant difference compared with CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates significant difference compared with DKD group, *p<0.05, **p<0.01, ***p<0.001);
[0046] Fig.15 This is a diagram of the expression of FN, Collage-1 and TGF-β1 in the kidney of DKD mice detected by Western Blot; GAPDH was used as the internal standard for statistics (# indicates a significant difference compared with the CON group, #p<0.05, ##p<0.01, ###p<0.001, * indicates a significant difference compared with the DKD group, *p<0.05, **p<0.01, ***p<0.001);
[0047] Fig.16 The effect of AMPs on the intestinal barrier of DKD mice (A is H&E staining of colon tissue, scale bar = 50 μm; B is immunofluorescence staining of colon ZO-1 (red), scale bar = 20 μm; C is the statistics of ZO-1 positive area; # indicates significant difference compared with CON-FMT group, #p<0.05, ##p<0.01, ###p<0.001, * indicates significant difference compared with DKD-FMT group, *p<0.05, **p<0.01, ***p<0.001);
[0048] Fig.17 This is a graph of the protein expression levels of colon tight junction molecules (ZO-1 and Occludin); GAPDH was used as the internal standard for statistics (# indicates a significant difference compared with the CON-FMT group, #p<0.05, ##p<0.01, ###p<0.001, * indicates a significant difference compared with the DKD-FMT group, *p<0.05, **p<0.01, ***p<0.001). DETAILED DESCRIPTION
[0049] It is worth noting that, unless otherwise specified, the raw materials used in the present invention are all common commercially available products, and their sources are not specifically limited.
[0050] Example 1
[0051] 1. Main experimental reagents, see Table 1.
[0052] Table 1 Main experimental reagents
[0053]
[0054] 2. Main instruments and equipment, see Table 2.
[0055] Table 2 Main instruments and equipment
[0056]
[0057] 3. Preparation of Atractylodes macrocephala polysaccharides (AMPs):
[0058] Step 1): After the Atractylodes macrocephala is pulverized, 10.0 g of the powder is accurately weighed, and the ratio of Atractylodes macrocephala powder to ultrapure water is 1:20 (g / mL), and the mixture is stirred and extracted at 90°C for 2 hours. The extract is centrifuged at 4000×r for 20 minutes in a high-speed refrigerated centrifuge, and the clear liquid and precipitate are collected.
[0059] Step 2): Extract and centrifuge the precipitate for the second time according to the method of step 1), combine the supernatants of the two extractions and concentrate them to 1 / 3 of the original volume by vacuum rotary evaporation at 60° C. to obtain a concentrate, and use iodine-potassium iodide reagent to detect the concentrate, and the results show that there is no starch.
[0060] Step 3): Add three times the amount of 95% volume fraction ethanol aqueous solution to the concentrate, stir and mix, and place at 4°C for alcohol precipitation overnight. Centrifuge the mixed solution after alcohol precipitation at 4000rpm for 10min, remove the supernatant, and collect the precipitate. Wash the precipitate twice with 95% volume fraction ethanol aqueous solution to make the polysaccharide component more uniform. Finally, dissolve the precipitate evenly in ultrapure water, and freeze-dry in vacuum for 48h to obtain Atractylodes macrocephala polysaccharides (AMPs).
[0061] The extraction rate and total sugar content of AMPs are shown in Table 3.
[0062] Table 3 Extraction rate and total polysaccharide content of Atractylodes macrocephala polysaccharide
[0063]
[0064] The results showed that the extraction rate of AMPs was 20.07% and the total sugar content was 87.06%.
[0065] 4. Preparation of Atractylodes macrocephala polysaccharide (AMPs-CM):
[0066] After the Atractylodes macrocephala was powdered, 10.0 g of Atractylodes macrocephala powder was accurately weighed and the first extraction was performed: at 80°C, the Atractylodes macrocephala powder and ultrapure water were stirred and extracted for 5 hours at a solid-liquid ratio of 1:15 (g / mL) to obtain an extract, and the extract was centrifuged at 4000 rpm for 20 minutes in a high-speed refrigerated centrifuge to collect the supernatant and residue of the first extraction. The residue was extracted for the second and third times according to the method of the first extraction, and the supernatants of the three extractions were combined and concentrated to 1 / 3 of the original volume by vacuum rotary evaporation at 60°C to obtain a concentrate. The iodine-potassium iodide reagent was used for detection, and the results showed that there was no starch in the concentrate. Three times the amount of 85% volume fraction ethanol aqueous solution was added to the concentrate, stirred and mixed, and placed at 4°C for alcohol precipitation overnight. The mixed solution after alcohol precipitation was centrifuged at 4000×r for 10 minutes, the supernatant was removed, and the precipitate was collected. The precipitate was then washed twice with an ethanol-water solution of equal volume fraction to make the polysaccharide component more uniform. Finally, the precipitate was evenly dissolved in ultrapure water and vacuum freeze-dried for 48 hours to obtain Atractylodes macrocephala polysaccharide (AMPs-CM).
[0067] 5. Monosaccharide composition analysis
[0068] The monosaccharide composition of AMPs and AMPs-CM was determined using a Thermo ICS5000 ion chromatography system and an electrochemical detector. 6.0 mg of AMPs and AMPs-CM were hydrolyzed with trifluoroacetic acid (2.0 mol / L) at 121°C for 2 h, connected to nitrogen, and blown dry. Then 99.99% methanol was added for washing, blown dry, and the washing was repeated 2-3 times. Sterile water was added to dissolve and transferred to a chromatographic bottle as the sample to be tested. Each setting was repeated 3 times. The AMPs samples were AMPs-1, AMPs-2 and AMPs-3. The mixed standard (MD) was prepared by proportioning fucose (Fuc), rhamnose (Rha), arabinose (Ara), galactose (Gal), glucose (Glc), xylose (Xyl), mannose (Man), fructose (Fru), ribose (Rib), galacturonic acid (Gal-UA), glucuronic acid (Glc-UA), mannuronic acid (Man-UA) and guluronic acid (Gul-UA) into a series of concentration gradients. Dionex TM CarboPac TM PA20 (150*3.0mm, 10μm) liquid chromatography column was used for detection.
[0069] The monosaccharide compositions of AMPs and AMPs-CM are shown in Table 4 .
[0070] Table 4 Monosaccharide composition percentage of AMPs and AMPs-CM
[0071]
[0072] The results showed that both AMPs and AMPs-CM were composed of monosaccharides glucose, arabinose, galactose, galacturonic acid and glucuronic acid. The ion chromatogram of the monosaccharide composition of AMPs is shown in Figure 2. Figure 1 As shown, AMPs are mainly composed of glucose (83.93%), in addition, they also contain small amounts of arabinose (7.19%), galactose (5.47%), galacturonic acid (3.00%) and glucuronic acid (0.41%).
[0073] 6. Infrared spectroscopy and scanning electron microscopy analysis of Atractylodes macrocephala polysaccharides (AMPs)
[0074] The infrared spectra of AMPs were analyzed using a Fourier transform infrared spectrometer to identify the functional group characteristics contained. A small amount of AMPs was weighed and mixed with 200 mg of potassium bromide, and then pressed into a sheet structure with a thickness of 1 mm for on-machine testing. Three repetitions were set up, and the AMPs samples were AMPs-1, AMPs-2, and AMPs-3, and were scanned and analyzed using a Fourier transform infrared spectrometer (Nicolet iZ-10).
[0075] Fourier transform infrared spectrometer was used in the frequency range (4000-400cm -1 ) record infrared spectra, Figure 2 is the Fourier-infrared spectrum of AMPs, Figure 2 It can be seen that at 3200cm -1 To 3600cm -1 The vibration region shown between 3000-2800cm -1 Within the range (2930cm -1 ) is the CH absorption peak, which includes CH, CH 2 and CH 3 Stretching vibration. At 1000-1200cm -1 The vibration range that appeared was caused by the vibration of the ester sugar group (CO-C) and the pyranose ring (COH), which proved that AMPs contain pyranose. Specifically, 905-876cm -1 The vibration range that appears in the range is caused by the β-configuration of glucan. 855-833cm -1 The vibration range that appears in the range is caused by the α-configuration of glucan.
[0076] A high-resolution field emission scanning electron microscope (Zeiss Merlin Compact) was used for electron microscopy analysis of Atractylodes macrocephala polysaccharides (AMPs). The polysaccharide sample was passed through a 100-mesh sieve, a small amount was taken on a conductive carbon tape, and after gold spraying, an electron microscope was used to scan and photograph, with a magnification of 100-4000 times.
[0077] The results are as follows Figure 3 As shown, Figure 3 The scanning electron microscope images of AMPs were observed at different magnifications (5k, 10k and 20k), showing a polysaccharide structure. The results showed that the surface of AMPs was loose and rough, with irregular multi-layer flakes or multi-layer rose petal distribution.
[0078] Example 2
[0079] Experimental drugs and experimental animals
[0080] Six-week-old male specific pathogen-free C57BL / 6 mice (16-18 g) were purchased from Guangdong Medical Animal Center. Animal production license number: SCXK (Guangdong) 2022-0002. All mice were raised in an SPF-grade sterile environment in the Animal Experimental Center of Guangdong Pharmaceutical University. Mice were maintained in an environment (12 h light-dark cycle, 20-25 ° C, relative humidity 60 ± 5%) with free access to food and water. The experimental mice were all adaptively fed for 1 week before the experiment. All animal experiments were carried out in accordance with the relevant provisions of the Animal Welfare Law of China and approved by the Laboratory Animal Ethics Committee of Guangdong Pharmaceutical University (No.gdpulacspf2022097).
[0081] Method for establishing DKD (diabetic nephropathy) mouse model: mice were fed a high-fat diet (18% fat, 50% carbohydrates, 19% protein) for 2 weeks, and then STZ (streptozotocin, 40 mg / kg) was intraperitoneally injected daily for 5 consecutive days to induce diabetes. After 7 days, the FBG (fasting blood glucose) of mice fasting for 6 hours was measured. If the FBG exceeded 11.1 mmol / L, the mice were considered diabetic.
[0082] Mice with different drug treatments were set up: All diabetic mice were randomly divided into 5 groups (8 mice in each group), including DKD model group (DKD, Saline), positive drug losartan group (LOS, 30 mg / kg / d), positive drug metformin (MET, 200 mg / kg / d), AMPs low-dose group (AMPs-L, 100 mg / kg / d), AMPs high-dose group (AMPs-H, 300 mg / kg / d) and AMPs-CM group (300 mg / kg / d). A control group (CON, Saline) was set up. The mice in the control group (CON, Saline) were fed with ordinary feed and injected with citric acid buffer for five consecutive days (8 mice in each group).
[0083] As an antihypertensive drug, losartan can effectively lower blood pressure and has the following adverse reactions: First, the impact on the neuropsychiatric system can be manifested as headache, dizziness, and some patients have insomnia. This adverse reaction is relatively mild and short-lived, and generally does not require termination of treatment. Second, hypotension, which is more common in patients who take excessive doses of drugs or are sensitive to antihypertensive drugs. Third, allergic reactions, including dermatitis, rash, and allergic edema. Fourth, gastrointestinal adverse reactions, mainly include nausea, vomiting, abnormal liver function, etc.
[0084] Example 3
[0085] Effects of Atractylodes macrocephala polysaccharide on renal inflammation in DKD mice
[0086] Hyperglycemia-induced kidney damage is closely related to the release of multiple inflammatory factors. Under hyperglycemia, kidney cells are damaged, leading to the initiation of inflammatory responses. This process involves the release of multiple inflammatory cytokines. The excessive release of these inflammatory factors can trigger an inflammatory response, leading to pathological changes in kidney tissue, including glomerular sclerosis, interstitial fibrosis, and tubular damage. With the progression of DKD, renal fibrosis often occurs, leading to irreversible loss of renal function and accelerating the process of renal failure. Collagen fibers are widely distributed in the body, and in the kidneys they mainly reflect the degree of damage and fibrosis. The intestinal mucosa performs its key protective function. Hyperglycemia-induced kidney damage may cause harmful bacteria and toxins to enter the blood through the intestines, causing the risk of enterogenic infection.
[0087] The mice treated with different medications obtained in Example 2 were used for the experiment. After 8 weeks of medication, the mice were anesthetized and killed, and samples were collected. The mRNA levels of inflammatory factors Ccl2, Il-1β, and Nlrp3 in the kidneys, and the mRNA levels of fibrosis-related indicators fibronectin (Fn1), collagen I (Col1a1), and transforming growth factor β1 (Tgfb1) were detected by q-PCR.
[0088] Establishment of FMT mouse model: In the fecal microbiota transplantation experiment, healthy male C57BL / 6 mice were divided into a fecal microbiota transplantation normal control group (CON-FMT) and a model group after adaptive feeding. The DKD mouse model was established according to the same method as in Example 2. After successful modeling, the mice in the model group were randomly divided into a fecal microbiota transplantation model group (DKD-FMT) (n=8), a fecal microbiota transplantation positive control group (LOS-FMT, 30 mg / kg / d) (n=8), a fecal microbiota transplantation Atractylodes macrocephala polysaccharide AMPs low-dose treatment group (AMPs-L-FMT, 100 mg / kg / d) (n=8), a fecal microbiota transplantation Atractylodes macrocephala polysaccharide AMPs high-dose treatment group (AMPs-H-FMT, 300 mg / kg / d) (n=8) and a fecal microbiota transplantation Atractylodes macrocephala polysaccharide AMPs-CM treatment group model group (AMPs-CM-FMT, 300 mg / kg / d) (n=8). Before the experiment, all mice were pretreated with an antibiotic mixture containing ampicillin (10 g / L), metronidazole (8 g / L), neomycin sulfate (10 g / L), and vancomycin (5 g / L) by gavage for one week. About 200 mg of fresh feces of donor mice was mixed with normal saline and centrifuged for 3 minutes to separate insoluble substances, and the supernatant was extracted for oral gavage once a day. After 8 weeks, the urine of mice was collected, anesthetized and euthanized, and then blood, kidney, and intestinal tissue samples were collected and stored at -80 ° C. The mRNA expression of colon tight junction molecules Zo-1, E-cadherin, Ocln, Cldn2, and Cldn4 was detected.
[0089] The specific details of fluorescence quantitative PCR (q-PCR) are as follows:
[0090] Trizol method to extract total RNA from tissues:
[0091] ① Cut about 20 mg of thawed kidney or colon tissue into a 1.5 mL EP tube, put 2 grinding steel beads in each EP tube to grind it thoroughly. Then add 1 mL Trizol and put it into a tissue homogenizer for homogenization (60 Hz, 2 min × 3 times). The homogenization module needs to be precooled in a -20 ° C refrigerator before use. After homogenization, let the homogenate stand at room temperature for 10 minutes.
[0092] ② Add 200 μL of chloroform to each EP tube, shake vigorously to mix the solution thoroughly, and place it on the table of the fume hood for 10 minutes.
[0093] ③ Set the centrifuge temperature to 4 degrees Celsius and the speed to 12000rpm. After the centrifuge is precooled to 4 degrees Celsius, put in the EP tube, set the time to 15 minutes, tighten the lid and start centrifugation. After the centrifuge is finished and the speed is displayed as 0, open the lid and carefully take out the EP tube. The upper colorless, clear and transparent solution in the EP tube contains the total RNA required for the experiment. Use a pipette to draw 400μL of the upper colorless, clear and transparent solution. Take another set of RNase-free EP tubes and mark the sample information on the tube cap to accommodate the solution just drawn. Be careful in this step to avoid taking the solution of other impurity layers in the tube.
[0094] ④ Use a pipette to accurately add 400μL of isopropanol to the EP tube, gently invert it upside down to mix the solution thoroughly, and repeat the inversion 30 times. After the inversion is completed, place it on the experimental table and wait for precipitation. The precipitation process takes about 10 minutes. Then set the centrifuge to centrifuge at 12000rpm at 4℃ for 10 minutes. After the centrifuge is finished and the speed is displayed as 0, open the lid and carefully take out the EP tube.
[0095] ⑤ At this time, you can observe white precipitate in the EP tube, which is the precipitated RNA. Discard the supernatant and inject 1mL of 75% ethanol pre-cooled on ice into the EP tube to fully rinse the precipitate for 3-5 times. After sufficient washing, centrifuge at 4℃, 12000rpm for 15min. After the centrifuge ends and the speed is displayed as 0, open the lid, carefully take out the EP tube, and use a pipette to carefully and slowly aspirate the supernatant. Be careful not to aspirate the precipitate to cause RNA loss.
[0096] ⑥ At this time, there is only RNA precipitate moistened by 75% ethanol in the tube. To reduce ethanol impurities in RNA, open the EP tube cap and put it in a fume hood to evaporate the ethanol. When the RNA precipitate appears translucent light white, it means that the precipitate is half dry. Add 25μL of nuclease-free water to each EP tube. This step is to dissolve the RNA. In order to fully dissolve the RNA, put the EP tube in a 65℃ oven and let it stand for 10 minutes. After the dissolution is completed, it is the RNA mother solution.
[0097] ⑦ To determine the quality of RNA, measure the RNA concentration and purity. If the concentration of the mother solution is too high, add DEPC water to dilute the RNA solution to 500ng / μL. Detect the A260 / A280 of the RNA solution. If it is 1.8-2.2, the purity is qualified. Those who fail to meet the requirements will not participate in subsequent experiments.
[0098] Reverse transcription reaction: Take part of the sample for agarose gel electrophoresis to evaluate RNA integrity. Complete RNA bands include 28S, 18S and 5S ribosomal RNA. 28S / 18S>2 means that the RNA integrity is high. Prepare a DNA removal system (DNA RraserBuffer: gDNA Eraser = 2:1), dilute it to 1 microgram per microliter according to the total RNA concentration of each sample, the total volume of the entire system is 10 microliters, and react at room temperature for 15 minutes. The next step is to prepare the reverse transcription RNA system. The system ratio is shown in Table 5:
[0099] Table 5 System for reverse transcription of RNA
[0100]
[0101] Place on ice and mix well, add DNA removal system, mix well, and finally perform amplification cycle (conditions: 37°C for 15 min, 85°C for 5 s) to obtain cDNA, which is stored at 4°C.
[0102] q-PCR and data processing: Prepare the PCR system according to Table 6:
[0103] Table 6 PCR system
[0104]
[0105] After mixing evenly, add the samples to the 96-well plate in the order of loading. Detection on the machine. After amplification cycles, data analysis results (relative quantification with gapdh or β-actin as internal standard gene).
[0106] The mRNA levels of inflammatory factors (pro-inflammatory cytokines Ccl2, Il-1β and inflammasome Nlrp3) in each treatment group are shown in Figure 2 Figure 4 As shown, Figure 4 Figure 2 is a graph of the mRNA levels of inflammatory factors Ccl2, Il-1β, and Nlrp3 (Relative mRNA represents the expression multiple of the corresponding related intestinal tight junction protein mRNA). The results showed that Ccl2, Il-1β, and Nlrp3 were significantly upregulated in DKD mice, and significantly decreased after AMPs administration. The therapeutic effect of AMPs-CM was lower than that of AMPs.
[0107] The mRNA levels of fibrosis-related indicators in each treatment group are as follows Figure 5 As shown, Figure 5Figure 2 is the mRNA level diagram of fibrosis-related indicators fibronectin (Fn1), collagen I (Col1a1) and transforming growth factor β1 (Tgfb1). The results show that the mRNA expression levels of Fn1, Col1a1 and Tgfb1 (TGFB1) were significantly increased in the renal tissue of DKD mice. After treatment with AMPs, AMPs-CM and LOS, the expression levels of FN, Collage-1 and TGFB1 were significantly reduced. LOS had the best efficacy, and the efficacy of AMPs was significantly higher than that of AMPs-CM. The increase of FN, Collage-1 and TGFB1 is a key marker of renal interstitial fibrosis. This shows that AMPs effectively intervene in DKD by inhibiting the expression of FN, Collage-1 and TGFB1, thereby alleviating renal interstitial fibrosis and improving the progression of DKD.
[0108] The mRNA levels of colon tight junction molecules Zo-1, E-cadherin, Ocln, Cldn2 (CLDN-2), and Cldn4 (CLDN-4) in each treatment group were as follows: Figure 6 As shown, Figure 6 Figure 2 is the mRNA level of colon tight junction molecules Zo-1, E-cadherin, Ocln, Cldn2 and Cldn4. The results showed that the mRNA expression levels of Zo-1, E-cadherin, Ocln, Cldn2 and Cldn4 were significantly decreased in the kidney tissue of DKD-FMT mice. The expression levels of ZO-1 and Occludin increased after treatment with AMPs, AMPs-CM and LOS. The results showed that AMPs and AMPs-CM could repair the damage of the intestinal mucosal barrier of DKD mice and restore the expression level of tight junction proteins, and the therapeutic effect of AMPs was significantly higher than that of AMPs-CM.
[0109] Example 4
[0110] Effects of AMPs on renal function (24h-urinary protein, urine protein / creatinine ratio and serum creatinine level) in DKD mice
[0111] The mice treated with different drugs obtained in Example 2 were used for the experiment. After each mouse was placed in a metabolic cage for 24 hours, urine samples were collected from the metabolic cage, centrifuged at 3000 rpm for 5 minutes, and placed in a -80°C refrigerator for later use after the sediment was removed. The serum creatinine and urine protein of the mice were measured using a creatinine determination kit and a urine protein quantitative test kit according to the instructions provided by the kit manufacturer. The results are shown in FIG. Figure 7 As shown, Figure 7The figure shows the effect of AMPs on the biochemical indicators of DKD mice, where A is the urine protein level (Albumiuria) of each group of mice, B is the urine protein / creatinine ratio (Urine Albumin / Creatinine Ratio) of each group of mice, and C is the serum creatinine content (Serum creatinne) of each group of mice.
[0112] 24h-urinary protein, urine protein / creatinine (UACR) ratio and serum creatinine level (Scr) are important indicators commonly used in clinical practice to evaluate renal function. Their abnormally elevated levels reflect the degree of damage to glomerular filtration function. Figure 7 The results showed that compared with the CON group, the 24h-urinary protein content level of mice in the DKD group was significantly increased, while the abnormal increase of 24h-urinary protein was significantly reduced after the administration of AMPs (high and low doses) and LOS. Similarly, the serum creatinine of DKD mice was reduced after the administration of AMPs and LOS, and the renal function of mice was improved. The results showed that the renal protective effect of AMPs on DKD mice can improve the renal function indicators of DKD mice (24h-urinary protein, urine protein / creatinine ratio and serum creatinine level).
[0113] Example 5
[0114] Effects of AMPs on blood glucose in DKD mice
[0115] (1) The mice treated with different medications obtained in Example 2 were used for the experiment. The weight of the mice was recorded once a week, and the random blood glucose of the mice was recorded once every 2 weeks. The effects of Atractylodes macrocephala polysaccharide on the weight and blood glucose of DKD mice were recorded after 8 weeks. Figure 8 As shown, Figure 8 The figure shows the effect of Atractylodes macrocephala polysaccharide on body weight and blood glucose of DKD mice, where A is the body weight change of mice in 8 weeks, and B is the fasting blood glucose of mice in the 8th week.
[0116] The results showed that the DKD group had a significant decrease in body weight compared with the CON group, while there was no significant difference between the MET group, AMPs-L group, and AMPs-H group. Figure 8 B is a blood glucose curve, and the results show that compared with the normal control group, the blood glucose of mice in the model control group increased significantly, and compared with the model control group, the blood glucose of mice in the AMPs group and MET group decreased significantly. It can be concluded that AMPs can significantly reduce the fasting blood glucose of diabetic nephropathy mice.
[0117] (2) Oral glucose tolerance test (OGTT) was performed on mice treated with different administration methods obtained in Example 2, and the effect of AMPs on glucose tolerance of DKD mice was detected 30 minutes after intragastric administration of glucose solution. Fig. 9 As shown, Fig. 9 The figure shows the effect of AMPs on glucose tolerance in DKD mice, where A is the line graph of oral glucose tolerance test of each group of mice (Blood glucose), and B is the area under the curve (AUC) statistic of the OGTT line graph (AUC of OGTT).
[0118] like Fig. 9 The results showed that the blood glucose of all mice reached a peak 30 minutes after oral administration of glucose solution, and then gradually decreased. Compared with the normal control group, the AUC value of OGTT of the mice in the model control group increased significantly, indicating that their glucose tolerance decreased significantly; AMPs treatment can improve the oral glucose tolerance of DKD mice and reduce the AUC value of OGTT.
[0119] Example 6
[0120] Effects of AMPs on renal injury in DKD mice
[0121] The mice treated with different medications obtained in Example 2 were used for the experiment.
[0122] (1) Sample collection
[0123] After 8 weeks of administration, the mice were anesthetized and euthanized. Blood was collected, and after the blood samples were allowed to stand for 30 minutes, they were centrifuged at 3000rpm for 10 minutes to obtain the supernatant, which was then frozen in a -80°C refrigerator. After the blood was taken, the mice were killed by dislocating the neck, and the mice were dissected to expose their internal organs. The gastrointestinal tissue was gently pushed aside with a cotton swab to reveal the two kidneys. The kidneys of the mice were carefully cut off, placed in pre-cooled PBS to absorb the blood and hair on the surface, and the kidney capsule was gently peeled off with tweezers to avoid damaging the integrity of the kidney cortex. After peeling off the kidney capsule, the kidneys were clipped out, and excess water was absorbed on filter paper. The two kidneys were weighed and placed, and photos were taken to record the kidney morphology. 1 / 2 of the right kidney tissue was placed in an embedding box and soaked in tissue fixative for making paraffin sections; the remaining kidney tissue was placed in an EP tube, quickly frozen in liquid nitrogen, and then transferred to a -80°C refrigerator for subsequent indicator testing.
[0124] (2) Preparation of tissue sections
[0125] ① Tissue fixation: After soaking in the fixative for 24 hours, take out the embedding box and rinse with running water for 30 minutes to remove excess tissue fixative.
[0126] ② Tissue dehydration: Add appropriate amount of dehydration reagent to the automatic dehydrator, set the dehydration program, place the tissue sample, and start dehydration.
[0127] ③ Tissue embedding: After dehydration is completed, take out the tissue, turn on the switches of the paraffin embedding machine and the freezing table in advance, and after the paraffin in the embedding machine melts, use tweezers to pick up the kidney tissue and place it in the embedding mold. Click the wax nozzle button of the embedding machine, and the melted wax will flow out. After covering the tissue in the film, transfer the mold to the freezing table to cool and solidify. After the wax block is completely solidified, disassemble the embedding mold and separate it from the tissue wax block. Keep the tissue in the center during the embedding process and avoid bubbles. The embedded wax block is stored at room temperature in a dry environment.
[0128] ④ Slicing: Before slicing, place the wax block on a freezing table to freeze it to increase the hardness of the wax block. The trimming thickness is 10 μm. When the wax slice containing tissue is cut out and the cut surface is flat, adjust the slice thickness to 4 μm, use tweezers to pick up the cut slice and put it into the slice spreader to flatten it. After the tissue slices are flattened, use a glass slide to pick up the slices and write the corresponding number information, put them in a slide box, and place them in an oven at 37 degrees Celsius to dry the moisture. After drying, store the paraffin slices in a dry environment at room temperature for pathological examination, and observe the kidney appearance and pathological manifestations of DKD mice.
[0129] (3) After pathological examination, hematoxylin-eosin (H&E) staining was performed on the kidneys
[0130] Place the paraffin sections in a slide rack and place in a 65°C oven for 1 hour;
[0131] Dewaxing of sections: xylene I 20 min → xylene II 20 min → anhydrous ethanol I 15 min → anhydrous ethanol II 15 min → 95% ethanol 10 min → 90% ethanol 5 min → 80% ethanol 5 min;
[0132] Soak in tap water for 5 minutes;
[0133] Soak in hematoxylin solution for 6 minutes and rinse in running water for 10 minutes;
[0134] Differentiate with 1% hydrochloric acid and ethanol, rinse with running water for 15 minutes to turn blue;
[0135] Immerse in eosin solution for 1 minute, then rinse with tap water;
[0136] Dehydration: 75% ethanol 2s → 85% ethanol 2s → 95% ethanol 2s → anhydrous ethanol 2s → xylene 2s → xylene 2s;
[0137] Air-dry and seal with neutral gum.
[0138] The appearance and pathological manifestations of the kidneys of DKD mice are as follows Fig.10 As shown, Fig.10The figures are the morphological diagrams of mouse kidneys, where A is the appearance of representative mouse kidneys in each group, B is the ratio of mouse kidney weight to body weight (Kidney index), and C is H&E staining of kidneys.
[0139] Fig.10 The results showed that the kidneys of DKD mice were significantly swollen and increased in weight, and the renal index (kidney weight / body weight*100%) increased significantly, while the administration of AMPs and LOS reversed this trend ( Fig.10 (A) H&E staining of kidney sections showed the pathological changes of glomeruli and tubulointerstitium in DKD mice. The results of H&E staining showed that mice in the DKD group showed pathological features of swollen and deformed glomeruli, edema and vacuolar changes in the tubules, and massive infiltration of inflammatory cells. Compared with the DKD group, the renal pathological features were significantly improved after the administration of AMPs and LOS, and the infiltration of inflammatory cells was also significantly reduced ( Fig.10 Middle C), indicating that AMPs can alleviate kidney damage in DKD.
[0140] Example 7
[0141] Effects of AMPs on renal inflammation in DKD mice
[0142] In order to study whether AMPs inhibit tubulointerstitial inflammation in DKD mice, the mice treated with different medications obtained in Example 2 were used to conduct experiments, and the expression of CD68 (macrophage marker protein) in the proximal tubules of the kidneys of diabetic mice was detected.
[0143] 1. Immunohistochemistry staining:
[0144] The paraffin sections obtained in Example 5 were placed in a slide rack and placed in a 65°C oven for 1 hour;
[0145] Dewaxing of sections: xylene I 20 min → xylene II 20 min → anhydrous ethanol I 15 min → anhydrous ethanol II 15 min → 95% ethanol 10 min → 90% ethanol 5 min → 80% ethanol 5 min;
[0146] Rinse with tap water for 5 minutes;
[0147] High temperature and high pressure repair: prepare sodium citrate buffer solution, add water to the pressure cooker, boil until boiling, pour sodium citrate solution into the beaker, put in tissue slices, seal with tin foil, cover the pot and boil until steam is discharged, and time for 15 minutes;
[0148] After venting, take out the beaker and let it cool naturally to room temperature;
[0149] Soak in distilled water for 2 minutes, let stand at room temperature for 10 minutes with 3% hydrogen peroxide, and wash with PBS buffer (PH = 7.2-7.4) for 5 minutes × 3 times;
[0150] Incubate with primary antibody: first use filter paper to absorb water, block with 1% BSA serum for 1 hour, and leave at room temperature. During this period, prepare the primary antibody working solution (FN / CD68:1% BSA=1:500), spin dry the blocking solution, wash with PBS for 5 minutes × 3 times, add the primary antibody dilution solution to completely cover the tissue surface, and incubate at 4°C overnight;
[0151] The next day, the cells were rewarmed for 30 minutes and washed with PBS 3 times / 5 minutes;
[0152] Incubate with secondary antibody: prepare secondary antibody diluent with 1% BSA in advance, incubate at room temperature for 1 hour, shake off the secondary antibody working solution on the slide, and wash with PBS buffer (PH = 7.2-7.4) 3 times / 5 minutes;
[0153] Color development: transfer to a dark place and use DAB color developer to develop the color. Pay attention to controlling the color development time to avoid excessive color development and false positive area.
[0154] Hematoxylin staining for 30 seconds, running water for 5 minutes; differentiation with 1% hydrochloric acid ethanol differentiation solution, washing with running water for 15 minutes;
[0155] Dehydrate, air dry, and seal with neutral gum.
[0156] The results are as follows Fig.11 As shown, Fig.11 The figure shows the effect of AMPs on renal inflammation in DKD mice, where A is the immunohistochemical staining of CD68 in mouse kidneys; B is the statistics of the positive area of CD68.
[0157] The results showed that AMPs administration could significantly reduce the expression of CD68 in the kidneys of DKD mice.
[0158] 2. Western Blot
[0159] Sample preparation: Use tweezers to pick up 2 grinding beads and put them into an EP tube. Take out the collected mouse kidney / colon tissue from the ultra-low temperature refrigerator, carefully cut about 20 mg and put it into the corresponding EP tube, and add 500 microliters of lysis solution (RIPA: PMSF = 100: 1). Put it into the tissue homogenizer for homogenization (60Hz, 2min×3 times). The homogenization module needs to be pre-cooled in a -20℃ refrigerator before use. After homogenization, let the homogenate stand at room temperature for 20 minutes. Centrifuge at 4℃, 12000rpm for 25 minutes, and transfer the supernatant to a new EP tube as the tissue protein mother solution. Use BCA quantification, prepare the working solution (A: B = 50: 1), add the protein mother solution + BCA working solution in sequence, react at 35℃ for 30 minutes, and measure the absorbance with an enzyme marker. Calculate the concentration of the protein mother solution by linear equation and balance the concentration, transfer to a new EP tube, add 10% bromophenol blue loading buffer (supernatant: loading buffer = 4:1), and mix well. Finally, put them into a 95℃ metal bath water bath, denature at high temperature for 10 minutes, and then obtain the protein working solution, which is stored in a -80℃ refrigerator.
[0160] Sample pretreatment: Before the experiment, take the above samples out of the -80℃ refrigerator, put them into a 95℃ metal bath for 3 minutes, and then vortex and spin.
[0161] Glue preparation: Install the long and short glass plates on the glue preparation rack to ensure that the two plates fit tightly together to avoid glue leakage during glue preparation. According to the required glue concentration, mix polyacrylamide, ultrapure water, SDS, 10% APS and TEMED in the required proportions, operate on ice, prepare the separation gel, and use a 5mL large pipette to pour it between the two plates. Then use a 200μL pipette to absorb anhydrous ethanol to quickly flatten the glue surface. Leave it at room temperature for 30 minutes, pour out the anhydrous ethanol after solidification, prepare concentrated gel in proportion (reagents are the same as above), and fill the upper layer of the separation gel. Then insert a clean tooth comb to avoid bubbles.
[0162] Electrophoresis: Fix the prepared electrophoresis gel in the electrophoresis slot, carefully place it in the electrophoresis box, and pour 1× electrophoresis solution to the scale line. Pull out the comb of each gel, first add 5μL marker to the first lane, and then slowly add 10μL protein working solution to the subsequent lanes in sequence. After the sample is loaded, start electrophoresis at 80 volts for 30 minutes. When all lanes are flush, adjust the voltage to 120 volts and continue electrophoresis until close to the bottom. The electrophoresis is complete.
[0163] Transfer: Pre-cut the PVDF membrane of the size corresponding to the electrophoresis gel, mark the upper left corner of each membrane with a pencil, and then pre-soak it in anhydrous methanol for 15 minutes for activation. Pour the pre-cooled 1× electrotransfer solution into the transfer tray in advance, prepare the electrotransfer clip and the required clean filter paper. Take out the electrophoresis gel after electrophoresis, cut off the excess gel after the upper concentrated gel and bromophenol blue, transfer it to the transfer tray for rinsing, clamp the PVDF membrane and gel tightly, and cut the gel of the same size as the membrane. Then transfer the tightly fitted membrane and gel to the transfer clip, with 3 layers of clean filter paper and sponge pads on each side, buckle the clip, and put it into the transfer tank. Then add the pre-cooled 1× electrotransfer solution. In order to keep the temperature low during the electrotransfer process, add ice packs to the electrotransfer box, place it in a 4°C refrigerator, 300 mA constant current, and transfer time for 90 minutes.
[0164] Blocking: After the transfer is completed, use tweezers to remove the membrane, place it in a membrane washing box, and rinse it 3 times with 1×TBST, 5 minutes each time. During this period, weigh 5g of skim milk powder, dissolve it in 1×TBST as a solvent, and make up to 50mL to prepare blocking milk solution. Pour the blocking milk solution to completely cover the membrane, and incubate at room temperature for 1 hour.
[0165] Primary antibody incubation: After blocking, pour out the blocking milk solution, remove the membrane with tweezers, place it in a clean membrane washing box, pour an appropriate amount of 1×TBST, and rinse it 3 times / 5 minutes each time. During this period, use a 50mL centrifuge tube to add primary antibody diluent: protein antibody = 1:1000 to prepare the primary antibody incubation solution, use tweezers to hold the membrane tightly in the 50mL centrifuge tube, pay attention to the protein-containing side facing inwards, in contact with the primary antibody incubation solution. Put it in a 4℃ refrigerator and rotate and incubate overnight.
[0166] Secondary antibody incubation: The next day, take out the membrane with tweezers, place it in a clean membrane washing box, pour in an appropriate amount of 1×TBST, and rinse it 3 times / 5 minutes each time. During this period, use a 50 ml centrifuge tube to add 5% skim milk powder: secondary antibody = 1:5000 to prepare the secondary antibody incubation solution, use tweezers to hold the membrane tightly in the centrifuge tube, pay attention to the protein-containing side facing inwards, in contact with the secondary antibody incubation solution. Incubate at room temperature for 1 hour.
[0167] Chemiluminescent development: Prepare chemiluminescent solution and mix well. Use tweezers to immerse the membrane in a light-proof box for 1 minute for color development. Then place it in a chemiluminescent instrument for exposure, photography and preservation.
[0168] The mRNA expression of proinflammatory cytokines Ccl2, Il-1β and inflammasome Nlrp3 in kidney was detected. Fig.12 As shown, Fig.12This is a diagram showing the expression of MCP-1 and NLRP3 in the kidneys of DKD mice detected by Western Blot (GAPDH is the internal reference, and Protein expression indicates the fold change of the corresponding protein expression).
[0169] Western blot was used to detect the protein expression of pro-inflammatory cytokine MCP-1 and inflammasome NLRP3. Fig.12 ), MCP-1 and Nlrp3 were significantly upregulated in DKD mice and significantly decreased after AMPs administration, these results suggest that AMPs can alleviate inflammation in the kidneys of DKD mice.
[0170] Example 8
[0171] Effects of AMPs on renal fibrosis in DKD mice
[0172] As DKD progresses, renal fibrosis often occurs, leading to irreversible loss of renal function and accelerating the process of renal failure. Collagen fibers are widely distributed in the body and mainly reflect the degree of damage and fibrosis in the kidney. In order to clarify the effect of AMPs on renal fibrosis in DKD mice, the following experiments were conducted.
[0173] 1. The mouse kidney tissue sections (obtained in Example 6) were subjected to Masson staining, and the positive areas were counted using Image J.
[0174] Masson staining:
[0175] Place the paraffin sections in a slide rack and place in a 65°C oven for 1 hour;
[0176] Dewaxing of sections: xylene I 20 min → xylene II 20 min → anhydrous ethanol I 15 min → anhydrous ethanol II 15 min → 95% ethanol 10 min → 90% ethanol 5 min → 80% ethanol 5 min;
[0177] Soak in tap water for 5 minutes;
[0178] Stain with prepared Weigert iron hematoxylin for 5 min and rinse with running water for 10 min;
[0179] Differentiate with 1% hydrochloric acid and ethanol, and rinse with running water for 10 minutes;
[0180] Use Masson bluing solution to return to blue;
[0181] Dye with Ponceau acid fuchsin solution for 5 min and rinse briefly with distilled water;
[0182] Dye with phosphomolybdic acid solution for 2 minutes, and treat with prepared weak acid working solution (distilled water: glacial acetic acid solution = 2:1) for 1 minute;
[0183] Pour off the supernatant, and directly drop the slices into aniline blue staining solution for 5 minutes without washing.
[0184] Weak acid solution treatment for 1 min;
[0185] Dehydration: 75% ethanol 2s → 85% ethanol 2s → 95% ethanol 2s → anhydrous ethanol 2s → xylene 2s → xylene 2s;
[0186] Air-dry and seal with neutral gum.
[0187] Masson staining results of mouse kidneys Fig.13 As shown, Fig.13 The figure shows the effect of AMPs on renal fibrosis in DKD mice, where A is Masson staining of mouse kidney and B is the statistics of the positive area of Masson staining (Fibroticarea represents the fibrosis area).
[0188] The results showed that compared with the CON group, the DKD group had obvious collagen deposition, significantly increased collagen fibers in the glomerular and tubular spaces, and glomerular sclerosis. Compared with the DKD group, the collagen fibers in the glomerular and tubular spaces of each drug-treated group were significantly reduced, indicating that AMPs can improve the level of renal fibrosis in DKD mice.
[0189] 2. Fibronectin plays a key role in renal tubulointerstitial fibrosis by promoting extracellular matrix remodeling, enhancing cell adhesion and migration, activating fibroblasts, and regulating inflammatory responses, leading to the formation and accumulation of fibrous tissue. Immunohistochemical staining (the method used in Example 7) was used to show the expression of Fibronectin protein, and the positive area was counted by Image J.
[0190] Immunohistochemical staining results Fig.14 As shown, Fig.14 The diagram shows the effect of AMPs on tubulointerstitial fibrosis in DKD mice, where A is CD68 immunohistochemical staining of mouse kidneys, and B is the statistics of the FN-positive area (Positive area of FN).
[0191] The results showed that the expression of Fibronectin protein in the DKD group was significantly higher than that in the control group, and its expression was significantly reduced in each drug-treated group, indicating that AMPs can improve the level of renal fibrosis in DKD mice.
[0192] 3. Detection of fibrosis-related genes in kidney by q-PCR and Western Blot (the method used in Example 7).
[0193] The results are as follows Fig.15 As shown, Fig.15 This is a diagram of Western Blot detection of the expression of FN, Collage-1 and TGF-β1 in the kidney of DKD mice, with GAPDH as the internal standard for statistics.
[0194] Western Blot analysis showed that ( Fig.15 ), the protein expression of FN, Collage-1 and TGF-β1 was also significantly increased. After AMPs and LOS treatment, the expression levels of FN, Collage-1 and TGF-β1 decreased. The increase of FN, Collage-1 and TGF-β1 is a key marker of renal interstitial fibrosis. AMPs effectively intervene in DKD by inhibiting the expression of FN, Collage-1 and TGF-β1, thereby alleviating renal interstitial fibrosis and improving the progression of DKD.
[0195] The results showed that treatment of diabetic nephropathy mice with a high dose of 300 mg / kg and a low dose of 100 mg / kg of AMPs could significantly repair the pathological characteristics of renal tissue, alleviate renal fibrosis, and reduce the expression of the macrophage marker CD68 in the kidney.
[0196] Example 9
[0197] Effects of AMPs on intestinal mucosal barrier damage in DKD mice
[0198] The FMT mouse model was established according to the method of Example 3 to obtain the mouse model CON-FMT, DKD-FMT and AMPs-FMT (i.e. AMPs-H-FMT) groups. After 8 weeks, gene expression analysis was performed.
[0199] To further evaluate the effect of AMPs on the intestinal integrity of DKD mice, H&E-stained tissue samples were detected. Zonula Occludens 1 (ZO-1) is a key component for building tight junctions. When the expression of ZO-1 is reduced or the activity is weakened, it interferes with the formation of tight junctions between cells, hinders the intestinal mucosa from performing its key protective function, and increases the risk of harmful bacteria and toxins entering the blood through the intestine, causing enterogenic infection. Therefore, immunohistochemical staining was used to show the expression of ZO-1 protein, and Image J was used to count the positive area.
[0200] Immunofluorescence staining:
[0201] Place the paraffin sections in a slide rack and place in a 65°C oven for 1 hour;
[0202] Dewaxing of sections: xylene I 20 min → xylene II 20 min → anhydrous ethanol I 15 min → anhydrous ethanol II
[0203] 15min→95% ethanol 10min→90% ethanol 5min→80% ethanol 5min;
[0204] Rinse with tap water for 5 minutes;
[0205] High temperature and high pressure repair: prepare sodium citrate buffer solution, add water to the pressure cooker, boil until boiling, pour sodium citrate solution into the beaker, put in tissue slices, seal with tin foil, cover the pot and boil until steam is discharged, and time for 15 minutes;
[0206] After venting, take out the beaker and let it cool naturally to room temperature;
[0207] Soak in distilled water for 2 minutes, let stand at room temperature for 10 minutes with 3% hydrogen peroxide, and wash with PBS buffer (PH = 7.2-7.4) for 5 minutes × 3 times;
[0208] Incubate with primary antibody: First, use filter paper to absorb water, block with 1% BSA serum for 1 hour, and leave at room temperature. During this period, prepare the primary antibody working solution (FN / CD68:1% BSA=1:500). Dry the blocking solution, wash with PBS for 5 minutes × 3 times. Add the primary antibody dilution solution to completely cover the tissue surface, and incubate at 4°C overnight.
[0209] The next day, rewarm the cells for 30 minutes and wash with PBS 3 times / 5 minutes.
[0210] Incubate with secondary antibody: Prepare secondary antibody diluent with 1% BSA in advance and incubate at room temperature for 1 hour. After shaking off the secondary antibody working solution on the slide, wash with PBS buffer (PH=7.2-7.4) 3 times / 5 minutes.
[0211] Transfer to a dark place, counterstain with DAPI for 10 minutes, wash with PBS for 5 minutes × 3 times, seal the slides, and store at -20℃.
[0212] H&E stained tissue samples and immunofluorescence staining results are shown in Fig.16 As shown, Fig.16 The diagram shows the effect of AMPs on the intestinal barrier of DKD mice, where A is H&E staining of colon tissue, B is immunofluorescence staining of colon ZO-1 (red), and C is the statistics of the positive area of ZO-1.
[0213] In H&E stained tissue samples ( Fig.16In the middle (A), the CON group showed normal colonic structure, while in the DKD group, the epithelial cell layer of the colon was destroyed, and the crypts and goblet cells were severely swollen and deformed, which was significantly reversed by oral administration of AMPs and LOS for 8 weeks. Immunofluorescence staining results showed ( Fig.16 BC), the expression of ZO-1 in the colon of the DKD group was inhibited, and the expression of ZO-1 was increased after AMPs treatment.
[0214] Intestinal tight junction proteins refer to a group of proteins that form tight junctions between intestinal epithelial cells. They are essential for maintaining intestinal barrier function and regulating intestinal permeability. These proteins prevent harmful substances and pathogens from entering the blood circulation by controlling the opening and closing of intercellular gaps, while allowing the absorption of nutrients. Tight junction factor-related genes in the colon were detected by q-PCR and Western Blot.
[0215] The results are as follows Fig.17 As shown, Fig.17 This is a graph of the protein expression levels of colon tight junction molecules (ZO-1 and Occludin), with GAPDH as the internal standard for statistics.
[0216] Western Blot Analysis Fig.17 ) showed that the protein expression of ZO-1 and Occludin was significantly decreased. After treatment with AMPs and LOS, the expression levels of ZO-1 and Occludin increased. AMPs can repair the damage of the intestinal mucosal barrier of DKD mice and restore the expression level of tight junction proteins.
[0217] In summary, the present invention uses STZ intraperitoneal injection combined with a high-fat diet to establish a diabetic nephropathy model, and studies the pharmacological and pharmacodynamic effects of AMPs on diabetic nephropathy. Studies have shown that AMPs have a significant improvement in fasting blood glucose and glucose tolerance in diabetic mice induced by STZ intraperitoneal injection combined with a high-fat diet, indicating that AMPs have a certain hypoglycemic effect and are expected to be used as a hypoglycemic drug for the treatment of diabetes. Studies on the therapeutic effect of diabetic nephropathy have shown that after AMPs treatment, various renal injury indicators such as kidney-related physiological and biochemical indicators (kidney weight to body weight ratio, 24h urine protein, serum creatinine), renal hypertrophy, renal fibrosis and inflammatory response in STZ-induced diabetic mice have been significantly improved, indicating that AMPs have a good effect in treating diabetic nephropathy, and can improve and delay the kidney damage, fibrosis and inflammatory process of diabetic nephropathy. Crucially, AMPs treatment can also repair the colon mucosal barrier function and restore the expression of marker proteins in the intestinal epithelium, which can provide new treatment strategies for diabetic nephropathy and / or diabetic intestinal diseases by regulating intestinal flora.
[0218] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. The use of Atractylodes macrocephala polysaccharide in the preparation of a drug for treating diabetes-related diseases, characterized in that: The diabetes-related diseases include diabetic nephropathy and / or diabetic bowel disease.
2. The application according to claim 1, characterized in that: The Atractylodes macrocephala polysaccharide is used to prepare a medicine for treating a mixed disease of diabetic nephropathy and diabetic intestinal disease, or diabetic nephropathy, wherein the diabetic nephropathy includes one or more of renal function damage, inflammation and renal fibrosis.
3. The application according to claim 1, characterized in that: The Atractylodes macrocephala polysaccharide is used to prepare a drug for treating a mixed disease of diabetic nephropathy and diabetic intestinal disease, or diabetic intestinal disease. The diabetic intestinal disease is intestinal mucosal damage, and the intestinal mucosal damage is: the expression of tight junction proteins in the intestinal mucosa is inhibited or the intestinal flora is disordered. The tight junction proteins include one or more of Zo-1, E-cadherin, Ocln, Cldn2 and Cldn4.
4. The use according to any one of claims 1 to 3, characterized in that: The Atractylodes macrocephala polysaccharide is prepared by a water extraction and alcohol precipitation method.
5. The application according to claim 4, characterized in that: The water extraction and alcohol precipitation method comprises the following steps: extracting Atractylodes macrocephala and water in a ratio of 1 g:15-25 mL, the extraction temperature being 85-95° C., the extraction times being 1-3 times, each extraction being 1-3 hours, combining the extracts and concentrating to obtain a concentrated solution; adding 90-100% by volume aqueous ethanol solution to the concentrated solution, the volume ratio of the concentrated solution to the ethanol aqueous solution being 1:2-4, performing alcohol precipitation to obtain a precipitate, and drying to obtain Atractylodes macrocephala polysaccharide.
6. The use according to claim 5, characterized in that: The extraction temperature is 90°C.
7. The use according to claim 6, characterized in that: The number of extractions was 2.
8. The use according to claim 7, characterized in that: The method further comprises washing the obtained precipitate with ethanol.
9. The use according to claim 8, characterized in that: The water extraction and alcohol precipitation method is specifically as follows: Step 1): extract Atractylodes macrocephala and ultrapure water at a ratio of 1 g: 20 mL at 90°C for 2 h, centrifuge at 4000 rpm for 20 min, and collect the supernatant and residue; Step 2): extract and centrifuge the residue for the second time according to the method of step 1), combine the supernatants of the two extractions and concentrate at 60° C. to 1 / 3 of the original volume to obtain a concentrated solution; Step 3): Add 3 times the volume of 95% ethanol aqueous solution to the concentrate, precipitate overnight at 4°C, centrifuge at 4000 rpm for 10 min, collect the precipitate, wash the precipitate twice with 95% ethanol aqueous solution, and freeze-dry to obtain Atractylodes macrocephala polysaccharide.
10. The use according to claim 9, characterized in that: The Atractylodes macrocephala polysaccharide is composed of 83.93% glucose, 7.19% arabinose, 5.47% galactose, 3.00% galacturonic acid and 0.41% glucuronic acid.
Citation Information
Patent Citations
Application of atractylodes macrocephala koidz polysaccharide in preparation of medicine for treating hepatic fibrosis
CN118304319A
Atractylodes macrocephala polysaccharide as well as gel and application thereof
CN118406167A
